Send me real-time posts from this site at my email

End of Day Briefing - Recap of Friday Nov. 20, 2020

Stocks lower on Friday as week ends with Pfizer sending vaccine approval request to FDA

The major averages slid on Friday following gains earlier in the week. Trading was mostly range-bound to close out the week as many cross-currents continue to tug at the markets, including the spreading virus, renewed restrictions, vaccine developments, stimulus uncertainties, and worrisome outlooks on the economy. Next week's volumes are certain to be lower with markets closed Thursday for Thanksgiving and open for a shortened session on Black Friday.

ECONOMIC EVENTS: In the U.S., the Fed and Treasury Secretary Steven Mnuchin appear to be divided on emergency lending facilities. Mnuchin indicated late yesterday in a letter to Fed Chair Jerome Powell that the Main Street Lending, corporate credit, and municipal credit programs would not be extended into 2021, with the leftover funds to be returned to the Treasury for reallocation. However, the Treasury Secretary indicated he will seek a 90-day extension for several other programs. Currently, all of the emergency programs under the CARES Act will expire on December 31. The Fed wrote back it would "prefer that the full suite of emergency facilities...continue to serve their important role as a backstop for our still strained and vulnerable economy." Mnuchin did also note that the facilities could be re-instituted with Congressional approval or with other Treasury funds.

Data from the Johns Hopkins Whiting School of Engineering shows there are now 57.2M confirmed cases of COVID-19 worldwide, including 11.7M in the U.S., and 1.36M deaths due to the disease, including about 253,000 in the U.S.

In energy news, Baker Hughes reported that the U.S. rig count is down 2 from last week to 310 rigs, with oil rigs down 5 to 231 rigs.

TOP NEWS: Pfizer ($PFE) and BioNTech ($BNTX) said they will submit a request today to the U.S. FDA for Emergency Use Authorization of their mRNA vaccine candidate, BNT162b2 against COVID-19, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020. The companies said their combined manufacturing network has the potential to supply up to 50M vaccine doses globally in 2020 and up to 1.3B doses by the end of 2021. CNBC later reported that Pfizer CEO Albert Bourla confirmed that the company has filed for emergency use authorization.

In other pharma news, U.S. President Donald Trump discussed new two new executive actions aimed at limiting drug prices in a press conference from the White House.

On the earnings front, shares of Foot Locker ($FL) were 5% lower despite the company's report of better than expected Q3 earnings and revenue. Of note, the company said on its quarterly conference call that the current economic environment may continue to pose challenges for the sneaker retailer.

Meanwhile, Workday ($WDAY) shares fell 9.3% despite the company reporting better than expected Q3 earnings and revenue and raising its fiscal 2021 subscription revenue guidance. Following the results, no fewer than three analysts raised their price targets on the shares, and Canaccord analyst Hynes David said that investors should buy Workday on the weakness.

FireEye ($FEYE) shares jumped 6.4% after the company announced a $400M strategic investment led by Blackstone Tactical Opportunities ($BX) to "support the company's vision to create the industry's leading intelligence-led cyber security platform and services company." Under the terms of its investment, Blackstone and ClearSky will purchase $400M in shares of a newly designated 4.5% Series A Convertible Preferred Stock of FireEye, with a purchase price of $1,000 per share. The Series A Preferred will be convertible into shares of FireEye's common stock at a conversion price of $18.00 per share. FireEye also announced that it had acquired Respond Software, a cybersecurity investigation automation company and creator of the Respond Analyst.

Additionally, Bloomberg reported that the European Union Aviation Safety Agency is set to publish its proposed airworthiness directive next week on Boeing's ($BA) 737 MAX, which would trigger a 28-day public consultation. The move would put Max on track for final clearance by year-end or in early 2021, Bloomberg added.

MAJOR MOVERS: Among the noteworthy gainers was Mesoblast ($MESO), which rose 16.9% after it reported quarterly results and entered into a global collaboration on Remestemcel-L with Novartis ($NVS). Also higher after reporting quarterly results was Williams-Sonoma ($WSM), which gained 6.4%.

Among the notable losers was Avrobio ($AVRO), which declined 17.6% after its 5M share spot secondary offering priced at $15 per share. Also lower were GSX Techedu ($GSX) and Post Holdings ($POST), which fell 8% and 6.4%, respectively, after reporting quarterly results.


  • Nasdaq Composite +32.1% YTD
  • S&P 500 +10.1% YTD
  • Russell 2000 +7.0% YTD
  • Dow Jones Industrial Average +2.5% YTD

Market Snapshot
Dow29263.42-219.75(-0.75%)
Nasdaq11854.89-49.74(-0.42%)
SP 5003557.54-24.33(-0.68%)
10-yr Note 0/320.831
NYSEAdv 1420 Dec 1602 Vol 951.5 mln
NasdaqAdv 1850 Dec 1684 Vol 5.3 bln

Industry Watch
Strong: Utilities, Health Care
Weak: Information Technology, Industrials, Financials

Moving the Market

-- Late-day selling in the technology sector and mega-caps

-- Treasury Secretary Mnuchin declines to extend several lending programs

-- Another positive vaccine update, but muted reaction


Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.

.

Want to trade some of these stocks?
Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!
Try2BeFunded
has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try.

Give Try2BeFunded a try!

.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue